Selpercatinib (new indication: thyroid cancer, RET-mutation, monotherapy, patients aged ≥ 12 years)

Subject:

• Active Substance: Selpercatinib
• Name: Retsevmo®
• Therapeutic area: Thyroid cancer
• Pharmaceutical company: Lilly Deutschland GmbH

Time table:

• Start: 01.10.2022
• Final decision by G-BA: 16.03.2023

Final decision:

• No additional benefit proved